Sports
Gain Posts Narrower Loss In Q2; Phase 1b Data For Rexaceract Due In Q4 2026
(RTTNews) - Gain Therapeutics, Inc. (GANX), a clinical-stage biotech company, reported a narrower second quarter loss due to lower operating expenses, higher interest income and a foreign exchange gain.